New Mexico Medicaid and GLP-1 coverage

The state names the four drugs it will not pay for. Its weight-reduction page prints a two-column table: under "Covered, Prior Authorization Required" it lists Didres (benzphetamine), Fastin (phentermine HCL), Meridia (sibutramine HCL M-hydrate), Sanorex (mazindol), Tenuate (phendimetrazine) and Xenical (orlistat); under "Not Covered by New Mexico Medicaid" it lists Imcivree (setmelanotide), Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide). For the covered column the criteria are a "BMI >40 or BMI > 35 with additional risk factors (hypertension, diabetes, dyslipidemia)" and "A six-month trial of caloric restriction and exercise is recommended (not required)." The page opens by scoping itself: "Some weight loss medications for treating obesity are covered under the New Mexico Medicaid Fee-for-Service program with prior authorization." It carries no revision date.

New Mexico Health Care Authority, Weight Reduction Medications · source

The exclusion is in the pharmacy regulation, not just on a web page. Under the heading "Noncovered Services or Service Restrictions," the rule states "MAD does not cover the following specific pharmacy items," and item (8) on that list is "weight loss/weight control drugs." The same list excludes fertility drugs, "cosmetic items, such as retin-A for aging skin, rogaine for hair loss," and "drug items used to treat sexual dysfunction."

New Mexico Administrative Code, 8.324.4.14 NMAC (Pharmacy Services, Prescribing, and Practitioner Administered Drug Items), effective January 2014 · source

The new statewide drug list has no GLP-1 class and no anti-obesity class. The list covers selected classes only, and its own table of contents runs from acne agents to coronary vasodilators with hypoglycemics broken out as alpha-glucosidase inhibitors, meglitinides, metformin, sulfonylureas and TZDs — no incretin or GLP-1 class among them. A full text extraction of the 116,282-character document returns zero occurrences of GLP, incretin, Ozempic, Mounjaro, Wegovy, Zepbound, Saxenda, obesity or weight. Its pages are footered "Last Update 6/29/2026."

New Mexico Health Care Authority Preferred Drug List (PDL), effective July 2026 · source

Being off the statewide list does not mean being uncovered — it means your plan decides. The state's own FAQ asks "How does this change affect drugs that are not included on the PDL?" and answers: "Drugs that are not on the PDL may still be covered. They will be independently managed by fee-for-service and each individual MCO." The same document dates the list — "The PDL will start on July 1, 2026" — and describes a transition period for members already filling a non-preferred drug that runs "until April 2027."

New Mexico Health Care Authority, Frequently Asked Questions — Medicaid Preferred Drug List (PDL), effective July 2026 · source

One Turquoise Care plan's own drug list contradicts itself on this. UnitedHealthcare Community Plan's New Mexico Medicaid PDL lists "Anti-obesity agents" among the categories that "are excluded from coverage under the outpatient pharmacy benefit and are not part of the UnitedHealthcare Community Plan PDL" — and then, sixteen hundred lines later, prints a class headed "Anti-Obesity Agents - Drugs for Weight Loss" containing exactly one entry: "WEGOVY SUBCUTANEOUS - Tier 2; PA; QL." Both statements are in the same document, effective July 1, 2026. This is the plan's publication, not the state's; a reader in that plan should get the answer in writing before relying on either line.

UnitedHealthcare Community Plan, New Mexico Medicaid Preferred Drug List (a plan document, not a state rule), effective July 2026 · source

New Mexico's hearing clock depends entirely on whether you are in a plan. The rule states that "an individual who is not enrolled in a MCO has 90 calendar days from the date of the 'notice of action' to request a HSD administrative hearing," and that to be timely the request "must be received by FHB, the individual's local income support division (ISD) office or by the MAD director's office no later than the close of business on the 90th calendar day" — or, if mailed, "postmarked by the 90th calendar day from the date of the notice of action." For someone in a managed care plan the same rule sets a much shorter second clock: a member may request a hearing only "after he or she has exhausted the MCO's appeal process" and "within 30 calendar days of the date of the MCO's final decision." Either way, keeping a benefit running while the appeal proceeds requires asking "within 10 calendar days of the mailing of the notice of action."

New Mexico Administrative Code, 8.352.2 NMAC (Administrative Hearings — Claimant Hearings), effective June 2014 · source

The plan-level step comes first and has its own window, and the two state rules do not fully agree on what follows it. The managed care rule gives a member "the right to request a MCO standard member appeal orally and in writing in accordance with his or her MCO procedures within 60 calendar days of the date of notice of an intended or taken adverse action," and adds that where the mailing date is disputed "the postmarked date will prevail." It then states that a member "must request a HSD expedited administrative hearing within 30 calendar days of the date of the MCO member appeal final decision letter or request a HSD standard administrative hearing within 90 days of the date of the MCO member appeal final decision" — where the claimant-hearings rule above gives 30 days for that step without distinguishing standard from expedited.

New Mexico Administrative Code, 8.308.15 NMAC (Managed Care Program — Grievances and Appeals), effective May 2018 · source